WEBINAR VIDEO | The N°1, healthy, rich in learning webinar about claims

WEBINAR VIDEO | The N°1, healthy, rich in learning webinar about claims
March 14, 2023

During this session, Mathieu Maniet, François Lambert and Karel Martens discuss the rules for No. 1 claims, cosmetic claims and health and nutrition claims, and give you an overview of the most important issues as well as practical guidelines.

Contact

  • Mathieu Maniet

    Managing Associate

  • François Lambert

    Associate

Recommended articles

June 05, 2025

Category Captains beware!: Belgian competition authority fines Category Management of OTC medicines

On 24 April 2025, the Belgian Competition Authority (BCA) announced a landmark decision imposing fines totaling over €11.2 million on three major pharmaceutical companies for their involvement in a long-running anti-competitive arrangement concerning the placement of over-the-counter (OTC) medicines in Belgian pharmacies..

Read on
March 17, 2025

The new Belgian government’s public health policy: 10 key take-aways for pharma policy

The new Belgian federal government has outlined its vision for public health in a policy paper under the slogan “More money for health, more health for our money”. Public health is a high-priority sector with a significant budget, and the policy paper introduces several key measures that will shape the pharmaceutical industry in the coming years. For pharma companies operating in Belgium, these developments bring both new regulatory challenges and strategic opportunities. Here is a focused analysis of ten key changes and their potential impact on the pharma industry.

Read on
March 13, 2025

CJEU’s DocMorris Ruling: where is the line for pharmaceutical advertising?

The intersection of pharmaceutical advertising, consumer protection, and internal market freedoms remains a complex legal battleground within the EU. In Apothekerkammer Nordrhein v. DocMorris NV (C-517/23), the Court of Justice of the European Union (CJEU) revisited the meaning of ‘advertising of medicinal products’, clarifying how far national restrictions on pharmaceutical advertisements can go under EU pharmaceutical law and internal market principles.

Read on